Intellia Therapeutics, Inc. (NASDAQ:NTLA) major shareholder Venture Fund Ix L.P. Atlas sold 150,000 shares of the business’s stock in a transaction that occurred on Tuesday, July 11th. The shares were sold at an average price of $16.24, for a total value of $2,436,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Intellia Therapeutics, Inc. (NTLA) traded up 0.44% during midday trading on Tuesday, reaching $16.13. The company’s stock had a trading volume of 238,686 shares. The firm has a 50 day moving average of $13.75 and a 200 day moving average of $13.83. Intellia Therapeutics, Inc. has a 52-week low of $10.83 and a 52-week high of $24.90. The firm’s market cap is $581.13 million.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings results on Tuesday, May 2nd. The company reported ($0.36) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.34) by $0.02. The business had revenue of $6.22 million for the quarter, compared to the consensus estimate of $5.30 million. Intellia Therapeutics had a negative return on equity of 17.65% and a negative net margin of 179.64%. Analysts anticipate that Intellia Therapeutics, Inc. will post ($1.58) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Venture Fund Ix L.P. Atlas Sells 150,000 Shares of Intellia Therapeutics, Inc. (NTLA) Stock” was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this piece can be read at https://www.americanbankingnews.com/2017/07/11/venture-fund-ix-l-p-atlas-sells-150000-shares-of-intellia-therapeutics-inc-ntla-stock.html.

NTLA has been the subject of several research analyst reports. Wedbush reiterated an “outperform” rating and issued a $25.00 price objective on shares of Intellia Therapeutics in a research report on Tuesday, March 14th. Zacks Investment Research lowered Intellia Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, March 18th. Chardan Capital initiated coverage on Intellia Therapeutics in a research report on Monday, March 27th. They issued a “buy” rating and a $19.00 price objective for the company. They noted that the move was a valuation call. Credit Suisse Group set a $24.00 price objective on Intellia Therapeutics and gave the company a “buy” rating in a research report on Wednesday, May 3rd. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $36.00 price objective on shares of Intellia Therapeutics in a research report on Thursday, June 22nd. One analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $25.71.

A number of hedge funds have recently modified their holdings of the company. Airain ltd acquired a new stake in shares of Intellia Therapeutics during the first quarter worth approximately $381,000. M&T Bank Corp acquired a new stake in shares of Intellia Therapeutics during the first quarter worth approximately $162,000. Paulson & CO. Inc. acquired a new stake in shares of Intellia Therapeutics during the first quarter worth approximately $1,107,000. Norges Bank acquired a new stake in shares of Intellia Therapeutics during the fourth quarter worth approximately $886,000. Finally, IHT Wealth Management LLC acquired a new stake in shares of Intellia Therapeutics during the first quarter worth approximately $117,000. Institutional investors and hedge funds own 47.06% of the company’s stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.

Receive News & Ratings for Intellia Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.